

Supporting Information
for
Copper-catalyzed [3 + 2] cycloaddition of
(phenylethynyl)di-*p*-tolylstibane with organic azides

Mizuki Yamada¹, Mio Matsumura¹, Yuki Uchida¹, Masatoshi Kawahata², Yuki Murata¹, Naoki Kakusawa³, Kentaro Yamaguchi² and Shuji Yasuike*¹

Address: ¹School of Pharmaceutical Sciences, Aichi Gakuin University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya 464-8650, Japan, ²Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido, Sanuki, Kagawa 769-2193, Japan and ³Faculty of Pharmaceutical Sciences, Hokuriku University, Ho-3 Kanagawa-machi, Kanazawa 920-1181, Japan

Email: Shuji Yasuike* - s-yasuik@dpc.agu.ac.jp

*Corresponding author

**Experimental procedures, full compound characterisation data and X-ray
crystallographic data**

Table of contents

1, General information	S2
2, Synthesis and characterization of (phenylethynyl)di- <i>p</i> -tolylstibane (1)	S2
3, Characterization of 5-stibanotriazoles (3)	S3
4, Reaction of 3a with HCl, I ₂ and NOBF ₄	S6
5, X-ray crystallographic data	S7
6, Copies of ¹ H and ¹³ C NMR spectra	S9
7, References	S24

General information

Melting points were measured on a Yanagimoto micro melting point hot-stage apparatus (MP-S3) and reported as uncorrected values. ^1H NMR (TMS: δ : 0.00 ppm as an internal standard) and ^{13}C NMR (CDCl_3 : δ : 77.00 ppm as an internal standard) and ^{19}F NMR (CCl_3F : 0.00 ppm as an extremal standard) spectra were recorded on JEOL JNM-AL400 (400 MHz and 100 MHz) and JNM-ECZ400S (400 MHz, and 376 MHz) spectrometers in CDCl_3 . Mass spectra were obtained on a JEOL JMP-DX300 instrument (70 eV, 300 μA). IR spectra were recorded on a Shimadzu FTIR-8400S spectrophotometer and reported in terms of frequency of absorption (cm^{-1}). Only selected IR bands are reported. Chromatographic separations were carried out using Silica Gel 60N (Kanto Chemical Co., Inc.). Thin-layer chromatography (TLC) was performed using Merck Pre-coated TLC plates (silica gel 60 F_{254}). Benzyl azide and azidomethyl phenyl sulfide were purchased from Wako Pure Chemical Industries and Sigma-Aldrich, respectively. Other azide compounds were prepared according to the published procedures (**2b** [1], **2c** [2], **2d**, **2i**, **2j** [3], **2e**, **2f** [4], **2h** [5, 6], **2k** [7]).

Synthesis and characterization of (phenylethynyl)di-*p*-tolylstibane (**1**)

(phenylethynyl)di-*p*-tolylstibane (**1**) were prepared according to the reported procedure [8]. An ether solution (50 mL) of di-*p*-tolylantimony(III) bromide, synthesized from redistribution of tri-*p*-tolylstibane (11.06 g, 28 mmol) and tribromoantimony (5.06 g, 14 mmol) was added dropwise at 0 $^\circ\text{C}$ to an ether solution (50 mL) of lithium acetylide, prepared from the appropriate phenylacetylene (42 mmol) and butyllithium (1.54 M solution in hexane, 42 mmol). After stirring the mixture at the same temperature for 2 h, the reaction mixture was diluted with ether (50 mL) and quenched with water. The reaction mixture was separated and the aqueous layer was extracted with ether (50 mL). The combined organic layer was dried over anhydrous MgSO_4 , and concentrated under reduced pressure. The residue was purified by silica gel chromatography (*n*-hexane/ CH_2Cl_2 = 5:1), affording compound **1** as colorless needles (11.56 g, 68% yield), mp 58–61 $^\circ\text{C}$ (from ether-methanol). ^1H NMR (400 MHz, CDCl_3) δ : 2.32 (6H, s), 7.16 (4H, d, J = 7.8 Hz), 7.28–7.31 (3H, m), 7.48–7.52 (2H, m), 7.61 (4H, d, J = 7.8 Hz). ^{13}C NMR (100 MHz, CDCl_3) δ : 21.4 (q), 86.0 (s), 110.9 (s), 123.4 (s), 128.2 (d), 128.4 (d), 129.8 (d), 132.0 (d), 134.4 (s), 135.5 (d), 138.7 (s). FTIR (KBr): 2363 cm^{-1} . LRMS (EI) m/z : 405 (M^+ , 75), 327 (10), 303 (45), 212 (100), 77 (20). Anal. Calc. for $\text{C}_{22}\text{H}_{19}\text{Sb}$: C, 65.22; H, 4.73. Found: C, 65.19; H, 4.58.

Characterization of 5-stibanotriazoles (3)

1-Benzyl-5-(di-*p*-tolylstibano)-4-phenyl-1*H*-1,2,3-triazole (3a)

Colorless prisms (250 mg, 93% yield), mp 128-129 °C (from *n*-hexane-CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ: 2.29 (6H, s), 5.32 (2H, s), 6.75 (2H, d, *J* = 7.3 Hz), 7.01 (4H, d, *J* = 8.3 Hz), 7.10-7.23 (10H, m), 7.45 (2H, m). ¹³C NMR (100 MHz, CDCl₃) δ: 21.3 (q), 53.9 (t), 126.8 (s), 127.0 (d), 127.6 (d), 127.7 (d), 127.9 (d), 128.3 (d), 129.0 (d), 129.9 (d), 130.7 (s), 131.9 (s), 135.6 (s), 135.7 (d), 139.1 (s), 156.5 (s). LRMS (FAB) *m/z*: 538 (M⁺, 40), 303 (12), 235 (25), 206 (100), 182 (82), 149 (50), 116 (70), 91 (40), 89 (25), 65 (20). Anal. Calc. for C₂₉H₂₆N₃Sb: C, 64.71; H, 4.87; N, 7.81. Found: C, 65.11; H, 4.88; N, 7.89.

1-(2-Bromobenzyl)-5-(di-*p*-tolylstibano)-4-phenyl-1*H*-1,2,3-triazole (3b)

Colorless plates (228 mg, 74% yield), mp 144-145 °C (from *n*-hexane-CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ: 2.27 (6H, s), 5.31 (2H, s), 6.11-6.13 (1H, m), 6.98 (4H, d, *J* = 7.3 Hz), 7.01-7.07 (2H, m), 7.14 (4H, d, *J* = 7.3 Hz), 7.29-7.36 (4H, m), 7.62-7.65 (2H, m). ¹³C NMR (100 MHz, CDCl₃) δ: 21.3 (q), 54.3 (t), 121.5 (s), 127.1 (d), 127.3 x 2 (s, d), 128.1 (d), 128.3 (d), 128.6 (d), 129.0 (d), 130.05 (d), 130.09 (s), 132.0 x 2 (s, d), 135.6 x 2 (s, d), 139.3 (s), 156.6 (s). LRMS (FAB) *m/z*: 618 (M⁺, 100), 303 (17), 236 (11), 206 (17), 169 (20), 91 (10). Anal. Calc. for C₂₉H₂₅BrN₃Sb: C, 56.43; H, 4.08; N, 6.81. Found: C, 56.58; H, 4.12; N, 6.97.

5-(Di-*p*-tolylstibano)-1-(naphthalen-1-ylmethyl)-4-phenyl-1*H*-1,2,3-triazole (3c)

Colorless prisms (229 mg, 78% yield), mp 156-157 °C (from *n*-hexane-CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ: 2.13 (6H, s), 5.79 (2H, s), 6.42 (1H, d, *J* = 7.3 Hz), 6.80 (4H, d, *J* = 7.8 Hz), 7.04 (4H, d, *J* = 7.8 Hz), 7.20-7.32 (4H, m), 7.35 (2H, d, *J* = 6.0 Hz), 7.41-7.46 (1H, m), 7.58-7.62 (2H, m), 7.68 (1H, d, *J* = 8.3 Hz), 7.78 (1H, d, *J* = 8.3 Hz). ¹³C NMR (100 MHz, CDCl₃) δ: 21.2 (q), 52.2 (t), 122.3 (d), 123.7 (d), 125.1 (d), 125.7 (d), 125.9 (d), 127.2 (s), 127.9 (d), 128.0 (d), 128.2 (d), 128.5 (d), 128.9 (d), 129.8 (d), 130.0 (s), 130.5 (s), 131.9 (s), 132.1 (s), 133.2 (s), 135.6 (d), 139.0 (s), 156.5 (s). LRMS (FAB) *m/z*: 588 (M⁺, 60), 303 (16), 182 (12), 141 (100), 91 (10). Anal. Calc. for C₃₃H₂₈N₃Sb: C, 67.37; H, 4.80; N, 7.14. Found: C, 67.05; H, 4.79; N, 7.15.

5-(Di-*p*-tolylstibano)-1-phenethyl-4-phenyl-1*H*-1,2,3-triazole (3d)

Colorless prisms (191 mg, 69% yield), mp 136-137 °C (from *n*-hexane-CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ: 2.33 (6H, s), 2.93 (2H, t, *J* = 8.3 Hz), 4.21 (2H, t, *J* = 8.3 Hz), 6.75 (2H, dd, *J* = 7.3 Hz, 3.9 Hz), 7.13 (4H, d, *J* = 7.8 Hz), 7.18-7.19 (3H, m), 7.26-7.30 (7H, m), 7.53-7.56 (2H, m). ¹³C NMR (100 MHz, CDCl₃) δ: 21.3 (q), 36.7 (t), 51.8 (t), 126.6 (d), 126.7 (s), 127.9 (d), 128.2 (d), 128.3 (d), 128.7 (d), 129.1 (d), 130.3 (d), 130.9 (s), 132.1 (s), 135.7 (d), 137.3 (s), 139.4 (s), 156.2 (s). LRMS (FAB) *m/z*: 552 (M⁺, 100), 303 (10), 105 (40), 91 (10). Anal. Calc. for C₃₀H₂₈N₃Sb: C, 65.24; H, 5.11; N, 7.61. Found: C, 65.51; H, 5.20; N, 7.69.

Ethyl 2-[5-(di-*p*-tolylstibano)-4-phenyl-1*H*-1,2,3-triazol-1-yl]acetate (3e)

Colorless prisms (208 mg, 78% yield), mp 92-94 °C (from *n*-hexane-CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ: 1.13 (3H, t, *J* = 7.0 Hz), 2.34 (6H, s), 3.92 (2H, q, *J* = 7.0 Hz), 4.78 (2H, s), 7.14 (4H, d, *J* = 8.3 Hz), 7.27-7.35 (7H, m), 7.60-7.63 (2H, m). ¹³C NMR (100 MHz, CDCl₃) δ: 13.8 (q), 21.4 (q), 51.4 (t), 61.7 (t), 127.6 (s), 128.1 (d), 128.3 (d), 128.9 (d), 130.2 (d), 130.8 (s), 132.0 (s), 136.0 (d), 139.5 (s), 156.2 (s), 166.6 (s). FTIR (KBr): 1751 cm⁻¹. LRMS (FAB) *m/z*: 534 (M⁺, 40), 303 (15), 241 (30), 185 (70), 149 (80), 93 (100), 75 (90). Anal. Calc. for C₂₆H₂₆N₃O₂Sb: C, 58.45; H, 4.91; N, 7.87. Found: C, 58.31; H, 4.88; N, 7.87.

1-Cinnamyl-5-(di-*p*-tolylstibano)-4-phenyl-1*H*-1,2,3-triazole (3f)

Colorless prisms (257 mg, 91% yield), mp 139-142 °C (from *n*-hexane-CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ: 2.31 (6H, s), 4.80 (2H, dd, *J* = 6.3 Hz, 1.5 Hz), 5.73 (1H, dt, *J* = 16.1 Hz, 6.3 Hz), 6.05 (1H, d, *J* = 16.1 Hz), 7.08-7.13 (6H, m), 7.21-7.31 (10H, m), 7.56-7.60 (2H, m). ¹³C NMR (100 MHz, CDCl₃) δ: 21.3 (q), 52.6 (t), 123.3 (d), 126.5 x 2 (s, d), 127.85 (d), 127.93 (d), 128.2 (d), 128.4 (d), 129.0 (d), 130.2 (d), 130.8 (s), 132.1 (s), 133.4 (d), 135.8 (d), 135.9 (s), 139.4 (s), 156.7 (s). LRMS (FAB) *m/z*: 564 (M⁺, 27), 303 (12), 297 (11), 241 (45), 221 (10), 185 (85), 149 (95), 93 (100), 75 (90), 57 (47), 45 (23), 31 (10). Anal. Calc. for C₃₁H₂₈N₃Sb: C, 65.98; H, 5.00; N, 7.45. Found: C, 65.72; H, 4.89; N, 7.43.

5-(Di-*p*-tolylstibano)-4-phenyl-1-[(phenylsulfanyl)methyl]-1*H*-1,2,3-triazole (3g)

Colorless prisms (205 mg, 72% yield), mp 73-74 °C (from *n*-hexane-AcOEt). ¹H NMR (400 MHz, CDCl₃) δ: 2.30 (6H, s), 5.22 (2H, s), 7.07 (4H, d, *J* = 7.8 Hz), 7.16-7.46 (10H, m), 7.34 (4H, d, *J* = 7.8 Hz). ¹³C NMR (100 MHz, CDCl₃) δ: 21.3 (q), 54.2 (t), 126.2 (s), 127.8 (d), 128.0 (d), 128.3 (d), 128.6 (d), 129.1 (d), 130.0 (d), 131.3 (s), 131.8 (s), 131.9 (s), 132.1 (d), 136.1 (d), 139.4 (s), 156.2 (s). LRMS (FAB) *m/z*: 570 (M⁺, 100), 303 (46), 236 (15), 182 (17), 123 (68), 91 (10). Anal. Calc. for C₂₉H₂₆N₃SSb: C, 61.07; H, 4.59; N, 7.37. Found: C, 61.16; H, 5.04; N, 7.42.

5-(Di-*p*-tolylstibano)-4-phenyl-1-[(phenylselanyl)methyl]-1*H*-1,2,3-triazole (3h)

Colorless prisms (225 mg, 73% yield), mp 93-94 °C (from *n*-hexane-AcOEt). ¹H NMR (400 MHz, CDCl₃) δ: 2.32 (6H, s), 5.32 (2H, s), 7.11 (4H, d, *J* = 7.3 Hz), 7.19-7.29 (6H, m), 7.34 (4H, d, *J* = 7.3 Hz), 7.37-7.39, (2H, m), 7.47-7.51 (2H, m). ¹³C NMR (100 MHz, CDCl₃) δ: 21.4 (q), 46.0 (t), 126.4 (s), 127.85 (s), 127.87 (d), 128.1 (d), 128.5 (d), 128.6 (d), 129.2 (d), 130.1 (d), 131.1 (s), 131.9 (s), 134.4 (d), 136.1 (d), 139.4 (s), 156.3 (s). LRMS (FAB) *m/z*: 618 (M+1⁺, 100), 462 (16), 369 (15), 303 (72), 236 (18), 182 (30), 105 (28), 91 (30). Anal. Calc. for C₂₉H₂₆N₃SbSe: C, 56.43; H, 4.25; N, 6.81. Found: C, 56.55; H, 4.36; N, 6.87.

5-(Di-*p*-tolylstibano)-1-octyl-4-phenyl-1*H*-1,2,3-triazole (3i)

Colorless oil (151 mg, 54% yield), ¹H NMR (400 MHz, CDCl₃) δ: 0.85-0.89 (5H, m), 0.98-1.05 (2H,

m), 1.07-1.21 (4H, m), 1.22-1.27 (2H, m), 1.38-1.46 (2H, m), 2.35 (6H, s), 3.93 (2H, t, $J = 7.8$ Hz), 7.16 (4H, d, $J = 7.8$ Hz), 7.28-7.34 (7H, m), 7.56-7.59 (2H, m). ^{13}C NMR (100 MHz, CDCl_3) δ : 14.1 (q), 21.3 (q), 22.6 (t), 26.4 (t), 29.01 (t), 29.04 (t), 30.9 (t), 31.7 (t), 51.1 (t), 126.1 (s), 127.9 (d), 128.2 (d), 129.0 (d), 130.2 (d), 130.9 (s), 132.2 (s), 135.7 (d), 139.4 (s), 156.3 (s). LRMS (FAB) m/z : 560 (M^+ , 100), 288 (20), 236 (12), 182 (15), 119 (40), 85 (38), 77 (15). HRMS (FAB) m/z : 559.1935 (Calc. for $\text{C}_{30}\text{H}_{36}\text{N}_3\text{Sb}$: 559.1947).

1-[2-(1, 3-Dioxolan-2-yl)ethyl]-5-(di-*p*-tolylstibano)-4-phenyl-1*H*-1,2,3-triazole (3j)

Colorless plates (162 mg, 59% yield), mp 130-132 °C (from *n*-hexane- CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 1.86-1.91 (2H, m), 2.34 (6H, s), 3.69-3.84 (4H, m), 4.10-4.14 (2H, m), 4.60 (1H, t, $J = 4.6$ Hz), 7.14 (4H, d, $J = 7.8$ Hz), 7.27-7.30 (7H, m), 7.52-7.55 (2H, m). ^{13}C NMR (100 MHz, CDCl_3) δ : 21.3 (q), 34.5 (t), 46.4 (t), 64.8 (t), 101.8 (d), 126.5 (s), 127.9 (d), 128.2 (d), 129.1 (d), 130.2 (d), 130.9 (s), 132.1 (s), 135.8 (d), 139.4 (s), 156.3 (s). LRMS (FAB) m/z : 548 (M^+ , 100), 303 (9), 182 (8). Anal. Calc. for $\text{C}_{27}\text{H}_{28}\text{N}_3\text{O}_2\text{Sb}$: C, 59.15; H, 5.15; N, 7.66. Found: C, 59.73; H, 5.22; N, 7.71.

3-[[5-(Di-*p*-tolylstibano)-4-phenyl-1*H*-1,2,3-triazol-1-yl]methyl]pyridine (3k)

Colorless prisms (146 mg, 54% yield), mp 101-102 °C (from *n*-hexane- CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ : 2.32 (6H, s), 5.27 (2H, s), 7.02-7.09 (6H, m), 7.18 (4H, d, $J = 7.8$ Hz), 7.27-7.34 (3H, m), 7.55-7.58 (2H, m), 7.92 (1H, s), 8.43 (1H, br). ^{13}C NMR (100 MHz, CDCl_3) δ : 21.3 (q), 51.4 (t), 123.2 (d), 126.9 (s), 128.1 (d), 128.2 (d), 129.0 (d), 130.2 (d), 130.3 (s), 131.4 (s), 131.8 (s), 134.6 (d), 135.7 (d), 139.6 (s), 148.1 (d), 148.8 (d), 157.0 (s). LRMS (FAB) m/z : 539 (M^+ , 100), 303 (18), 207 (30), 206 (20), 182 (19), 119 (15), 93 (62), 92 (22). Anal. Calc. for $\text{C}_{28}\text{H}_{25}\text{N}_4\text{Sb}$: C, 62.36; H, 4.67; N, 10.39. Found: C, 62.51; H, 4.87; N, 10.42.

Reaction of **3a** with HCl, I₂ and NOBF₄

1-Benzyl-4-phenyl-1*H*-1,2,3-triazole (**4**) [9]

1-Benzyl-5-(di-*p*-tolylstibano)-4-phenyl-1*H*-1,2,3-triazole (**3a**) (0.25 mmol) and 10% HCl (8 mL) in THF (8 mL) was stirred at room temperature for 5 min. After dilution with water (20 mL), the mixture was extracted with Et₂O (20 mL × 2). The organic layer was collected, dried over MgSO₄, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (*n*-hexane/AcOEt = 4:1), affording compound **4** as colorless needles (58 mg, 98% yield), mp 126 °C (from *n*-hexane–CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ: 5.58 (2H, s), 7.31-7.42 (8H, m), 7.66 (1H, s), 7.80 (2H, d, *J* = 7.8 Hz). ¹³C NMR (100 MHz, CDCl₃) δ: 54.1 (t), 119.4 (d), 125.6 (d), 127.9 (d), 128.1 (d), 128.6 (d), 128.7 (d), 129.0 (d), 130.4 (s), 134.6 (s), 148.1 (s). LRMS (EI) *m/z*: 235 (M⁺, 13), 206 (60), 180 (11), 116 (100), 91 (87), 65 (20). Anal. Calc. for C₁₅H₁₃N₃: C, 76.57; H, 5.57; N, 17.86. Found: C, 76.77; H, 5.69; N, 17.64.

1-Benzyl-5-iodo-4-phenyl-1*H*-1,2,3-triazole (**5**) [9]

To a solution of 1-benzyl-5-(di-*p*-tolylstibano)-4-phenyl-1*H*-1,2,3-triazole (**3a**, 269 mg, 0.5 mmol) in THF (3 mL) was added a solution of iodine (140 mg, 0.55 mmol) in THF (3 mL) at 0 °C. Then reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with aqueous Na₂S₂O₃. The organic layer was collected, dried over MgSO₄, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (*n*-hexane/AcOEt = 4:1), affording compound **5** as colorless prisms (128 mg, 71% yield), mp 137-138 °C (from *n*-hexane–CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ: 5.68 (2H, s), 7.30-7.48 (8H, m), 7.94 (2H, d, *J* = 7.3 Hz). ¹³C NMR (100 MHz, CDCl₃) δ: 54.4 (t), 76.4 (s), 127.4 (d), 127.8 (d), 128.5 (d), 128.5 (d), 128.6 (d), 128.9 (d), 130.2 (s), 134.3 (s), 150.2 (s). LRMS (EI) *m/z*: 361 (M⁺, 13), 234 (22), 206 (95), 179 (27), 115 (11), 91 (100), 65 (14). Anal. Calc. for C₁₅H₁₂N₃: C, 49.88; H, 3.35; N, 11.63. Found: C, 50.12; H, 3.54; N, 11.77.

(1-Benzyl-4-phenyl-1*H*-1,2,3-triazol-5-yl) difluorodi-*p*-tolylstibane (**6**)

To a solution of 1-benzyl-5-(di-*p*-tolylstibano)-4-phenyl-1*H*-1,2,3-triazole (**3a**, 269 mg, 0.5 mmol) in CH₂Cl₂ (3 mL) was added a solution of nitrosyl tetrafluoroborate (177 mg, 1.5 mmol) in THF (3 mL) at –20 °C. The mixture was stirred at –20 °C for 1 h; then, the temperature was allowed to increase to 0 °C, and the mixture was stirred for 4 h. The reaction mixture was diluted with CH₂Cl₂ (30 mL) and washed with water. The organic layer was collected, dried over MgSO₄, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (*n*-hexane/AcOEt = 3:1) to obtain, compound **6** as a colorless oil (244 mg, 85% yield). ¹H NMR (400 MHz, CDCl₃) δ: 2.32 (6H, s), 5.70 (2H, s), 6.69 (2H, d, *J* = 7.3 Hz), 6.98-7.20 (10H, m), 7.45 (2H, d, *J* = 7.3 Hz), 7.66 (4H, d, *J* = 8.3 Hz). ¹³C NMR (100 MHz, CDCl₃) δ: 21.5 (q), 54.4 (t), 126.5

(d), 127.7 (d), 127.9 x 2 (s, d), 128.4 (d), 128.6 (d), 129.4 (d), 130.2 (s), 130.6 (d), 134.9 (s), 135.1 (d), 143.4 (s), 154.5 (s). ^{19}F NMR (376 MHz, CDCl_3) δ : -135.2. LRMS (FAB) m/z : 576 (M^+ , 68), 583 (28), 466 (16), 288 (50), 206 (35), 154 (86), 119 (100), 91 (85), 85 (85), 39 (20). HRMS (FAB) m/z : 575.1144 (Calc. for $\text{C}_{29}\text{H}_{26}\text{F}_2\text{N}_3\text{Sb}$: 575.1133).

X-ray crystallographic data

The X-ray diffraction measurements of compounds **3a** were carried out using a 100 K Bruker APEX II CCD area-detector diffractometer using Mo $K\alpha$ radiation ($\lambda = 0.71073 \text{ \AA}$). The SADABS software was used for absorption correction. The structure was solved by direct methods using SHELXS-97 [10] followed by successive refinements using the full-matrix least-squares method on F^2 using SHELXL-2014 [11]. All the nonhydrogen atoms were refined anisotropically, whereas the hydrogen atoms were refined isotropically.

Crystal data of **3a**

$\text{C}_{29}\text{H}_{26}\text{N}_3\text{Sb}$, $M = 538.28$, $0.19 \times 0.18 \times 0.18 \text{ mm}$, monoclinic $P21/n$, $Z = 8$, $D_{\text{calc}} = 1.472 \text{ Mg/m}^3$, $a = 13.6590(12)$, $b = 20.2294(18)$, $c = 17.5830(16) \text{ \AA}$, $\beta = 91.1810(10)^\circ$, $V = 4857.4(8) \text{ \AA}^3$, The final R_1 and wR_2 were 0.0298 and 0.0677 ($I > 2\sigma(I)$).

The experimental and refinement details of the X-ray crystallographic structures of compound can be obtained free of charge from the Cambridge Crystallographic Data Centre (<http://www.ccdc.cam.ac.uk>), CCDC 1470151.






Figure S1: ORTEP drawing of compound **3a** with 50% probability (two independent molecules in the asymmetric unit). All hydrogen atoms are omitted for clarity.



Copies of ^1H and ^{13}C NMR spectra

^1H NMR of **1**




^{13}C NMR of **1**




¹H NMR of **3a** ^{13}C NMR of **3a**


¹H NMR of **3b**




¹³C NMR of **3b**




¹H NMR of **3c**




¹³C NMR of **3c**





¹H NMR of **3d**




¹³C NMR of **3d**




¹H NMR of **3e** ^{13}C NMR of **3e**


¹H NMR of **3f**




¹³C NMR of **3f**




¹H NMR of **3g**




¹³C NMR of **3g**





¹H NMR of **3h**




¹³C NMR of **3h**




¹H NMR of **3i** ^{13}C NMR of **3i**


¹H NMR of **3j**




¹³C NMR of **3j**




¹H NMR of **3k**




¹³C NMR of **3k**




¹H NMR of 4




¹³C NMR of 4




¹H NMR of 5




¹³C NMR of 5



¹H NMR of 6



¹³C NMR of 6



References

1. Hong, L.; Lin, W.; Zhang, F.; Liu, R.; Zhou, X. *Chem. Commun.* **2013**, 49, 5589–5591.
2. Suzuki, T.; Ota, Y.; Ri, M.; Bando, M.; Gotoh, A.; Itoh, Y.; Tsumoto, H.; Tatum, P. R.; Mizukami, T.; Nakagawa, H.; Iida, S.; Ueda, R.; Shirahige, K.; Miyata, N. *J. Med. Chem.* **2012**, 55, 9562–9575.
3. Alvarez, S. G.; Alvarez, M. T. *Synthesis* **1997**, 413–414.
4. Campbell-Verduyn, L. S.; Mirfeizi, L.; Dierckx, R. A.; Elsinga, P. H.; Feringa, B. L. *Chem. Commun.* **2009**, 2139–2141.
5. Huang, X.; Duan, D.-H. *Synlett* **1998**, 1191–1192.
6. Seus, N.; Saraiva, M. T.; Alberto, E. E.; Savegnago, L.; Alves, D. *Tetrahedron* **2012**, 68, 10419–10425.
7. Brotherton, W. S.; Clark, R. J.; Zhu, L. *J. Org. Chem.* **2012**, 77, 6443–6455.
8. Kakusawa, N.; Yamaguchi, K.; Kurita, J. *J. Organomet. Chem.* **2005**, 690, 2956–2966.
9. Zhou, Y.; Lecourt, T.; Micouin, L. *Angew. Chem. Int. Ed.* **2010**, 49, 2607–2610.
10. Sheldrick, G. M. *Acta Cryst.* **2008**, A64, 112–122.
11. Sheldrick, G. M. SHELXTL Version 2014/7. <http://shelx.uni-ac.gwdg.de/SHELX/index.php>.